CompuGroup Medical SE KGaA Future Growth
Future criteria checks 4/6
CompuGroup Medical SE KGaA is forecast to grow earnings and revenue by 28.8% and 3.8% per annum respectively. EPS is expected to grow by 28.7% per annum. Return on equity is forecast to be 13.5% in 3 years.
Key information
28.8%
Earnings growth rate
28.7%
EPS growth rate
Healthcare Services earnings growth | 28.7% |
Revenue growth rate | 3.8% |
Future return on equity | 13.5% |
Analyst coverage | Good |
Last updated | 26 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,355 | 120 | 102 | 250 | 7 |
12/31/2025 | 1,298 | 117 | 135 | 229 | 10 |
12/31/2024 | 1,241 | 94 | 90 | 182 | 10 |
12/31/2023 | 1,228 | 46 | 112 | 180 | N/A |
9/30/2023 | 1,247 | 76 | 135 | 201 | N/A |
6/30/2023 | 1,249 | 89 | 123 | 193 | N/A |
3/31/2023 | 1,214 | 70 | 82 | 157 | N/A |
12/31/2022 | 1,175 | 73 | 69 | 145 | N/A |
9/30/2022 | 1,127 | 72 | 45 | 122 | N/A |
6/30/2022 | 1,116 | 71 | 58 | 140 | N/A |
3/31/2022 | 1,088 | 76 | 88 | 165 | N/A |
12/31/2021 | 1,063 | 69 | 94 | 165 | N/A |
9/30/2021 | 1,021 | 66 | 88 | 155 | N/A |
6/30/2021 | 975 | 72 | 111 | 166 | N/A |
3/31/2021 | 915 | 71 | 113 | 168 | N/A |
12/31/2020 | 869 | 73 | 94 | 150 | N/A |
9/30/2020 | 833 | 77 | 86 | 128 | N/A |
6/30/2020 | 779 | 60 | 34 | 80 | N/A |
3/31/2020 | 781 | 58 | 60 | 107 | N/A |
12/31/2019 | 770 | 66 | 67 | 110 | N/A |
9/30/2019 | 757 | 87 | 83 | 137 | N/A |
6/30/2019 | 742 | 86 | 123 | 170 | N/A |
3/31/2019 | 747 | 97 | 109 | 155 | N/A |
12/31/2018 | 736 | 96 | 97 | 136 | N/A |
9/30/2018 | 707 | 65 | 73 | 112 | N/A |
6/30/2018 | 678 | 52 | 64 | 109 | N/A |
3/31/2018 | 624 | 39 | 61 | 101 | N/A |
12/31/2017 | 599 | 31 | 44 | 86 | N/A |
9/30/2017 | 586 | 41 | N/A | 89 | N/A |
6/30/2017 | 583 | 46 | N/A | 80 | N/A |
3/31/2017 | 578 | 47 | N/A | 78 | N/A |
12/31/2016 | 571 | 45 | N/A | 68 | N/A |
9/30/2016 | 562 | 41 | N/A | 67 | N/A |
6/30/2016 | 553 | 36 | N/A | 68 | N/A |
3/31/2016 | 556 | 27 | N/A | 55 | N/A |
12/31/2015 | 553 | 38 | N/A | 73 | N/A |
9/30/2015 | 548 | 34 | N/A | 41 | N/A |
6/30/2015 | 547 | 40 | N/A | 31 | N/A |
3/31/2015 | 535 | 42 | N/A | 35 | N/A |
12/31/2014 | 525 | 26 | N/A | 32 | N/A |
9/30/2014 | 511 | 29 | N/A | 55 | N/A |
6/30/2014 | 496 | 24 | N/A | 51 | N/A |
3/31/2014 | 479 | 18 | N/A | 45 | N/A |
12/31/2013 | 470 | 24 | N/A | 52 | N/A |
9/30/2013 | 462 | 19 | N/A | 50 | N/A |
6/30/2013 | 458 | 20 | N/A | 54 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: COPD's forecast earnings growth (28.8% per year) is above the savings rate (1.6%).
Earnings vs Market: COPD's earnings (28.8% per year) are forecast to grow faster than the UK market (12.3% per year).
High Growth Earnings: COPD's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: COPD's revenue (3.8% per year) is forecast to grow faster than the UK market (3.4% per year).
High Growth Revenue: COPD's revenue (3.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: COPD's Return on Equity is forecast to be low in 3 years time (13.5%).